News
-
-
-
COMMUNIQUÉ RÉGLEMENTÉ
Novembre 2025 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Communiqué mensuel sur le nombre de droits de vote et d'actions de la société bioMérieux. Informations conformes à la réglementation financière en vigueur -
-
-
-
COMMUNIQUÉ DE PRESSE
Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term Extension Results, Highlighting the Therapy's Potential for Patients with Hereditary Hemorrhagic Telangiectasia
Vaderis Therapeutics announces publication of engasertib proof-of-concept study results in The New England Journal of Medicine, showing potential for Hereditary Hemorrhagic Telangiectasia patients -
COMMUNIQUÉ DE PRESSE
Hardman & Co research on Real Estate Credit Investments (RECI): Investor Day: opportunities aplenty
Hardman & Co Research highlights Real Estate Credit Investments opportunities post Investor Day. Expertise in unique real estate lending sectors drives strong pipeline and good returns -
COMMUNIQUÉ DE PRESSE
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Aspire Biopharma Holdings, Inc. submits Pre-IND meeting request to FDA for fast-acting sublingual aspirin formulation to treat acute myocardial infarction, demonstrating rapid action and potential for FDA approval -
COMMUNIQUÉ DE PRESSE
Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
Jaguar Health, Inc. requests advice from EMA on EU approval pathway for Canalevia® in treating general diarrhea in dogs. Novel non-antibiotic approach targets a significant market gap
